-90%

est. 2Y upside i

HealthcareSeed

We make carbon negative chemicals from CO2 using fermentation

Rank

#2371

Sector

Biotechnology, Carbon Recycling, Materials & Manufacturing

Est. Liquidity

~7Y

Data Quality

Data: Low

Phase Biolabs offers a high-risk, high-reward opportunity in a critical climate tech sector, but job seekers should weigh the significant capital intensity and strong incumbent competition against the promising early technology and market potential.

Last updated: February 16, 2026

Bull (15%)+400%

The proprietary biocatalyst and early pilots lead to a successful, large Series A/B round, proving scalability and attracting major customers in the rapidly growing CCU market.

Base (40%)+50%

The company secures additional funding and some commercial contracts, but scaling is slower and more capital-intensive than expected, leading to moderate valuation growth.

Bear (45%)-90%

The company struggles to secure follow-on funding, faces significant technical hurdles, or is outcompeted by larger incumbents, leading to a substantial loss of equity value.

Est. time to liquidity~7.0 years

General — 1 role

View all 1 open roles at Phase Biolabs →

Last updated: March 10, 2026

Community

Valuation Sentiment

Our model estimates -90% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.